• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

T0期分化型甲状腺癌患者的意外预后:2004 - 2013年监测、流行病学和最终结果(SEER)数据库分析

Unanticipated prognosis of differential thyroid cancer patients with T0 stage: analysis of the SEER database 2004-2013.

作者信息

Liu Chunping, Ming Jie, Zeng Wen, Wang Shuntao, Xiong Yiquan, Zhao Qiuyang, Yin Xingjie, Liu Zeming, Huang Tao

机构信息

Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Department of Ophthalmology, Zhongnan Hospital, Wuhan University, Wuhan, China.

出版信息

Oncotarget. 2017 Aug 7;8(41):70777-70787. doi: 10.18632/oncotarget.19988. eCollection 2017 Sep 19.

DOI:10.18632/oncotarget.19988
PMID:29050318
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5642593/
Abstract

The prognosis of T0 stage differentiated thyroid cancer (DTC) remains unclear. This study aimed to investigate the prognosis of T0 stage DTC patients to provide a new perspective on treatment guidelines for these patients. We investigated a large cohort of DTC patients from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2013. Patient survival curves were examined by Kaplan-Meier analyses with log-rank tests and Cox proportional hazards regression analyses. In the study cohort, the rate of cancer-specific mortality per 1000 person-years for T0 was higher than T1-T3, but lower than T4. The all-cause mortality for T0 patients was higher than all other stages (T1-T4). Multivariate Cox regression modeling showed that T0 had a significant risk for cancer-specific mortality when compared to T1 and T4, but not T2 or T3, after adjustment for other risk factors. For all-cause mortality, T0 showed a significant risk for all-cause mortality when compared to T4, but not T1-T3 stage patients. Similar results were obtained after matching for influential factors using propensity scored matching analysis. The unanticipated prognosis of T0 stage DTC patients was found to be not better than of other stage DTC patients, providing new implications for the treatment of T0 stage DTC patients.

摘要

T0期分化型甲状腺癌(DTC)的预后仍不明确。本研究旨在调查T0期DTC患者的预后,为这些患者的治疗指南提供新的视角。我们调查了2004年至2013年期间来自监测、流行病学和最终结果(SEER)数据库的一大群DTC患者。通过Kaplan-Meier分析、对数秩检验和Cox比例风险回归分析来检查患者生存曲线。在研究队列中,T0期每1000人年的癌症特异性死亡率高于T1-T3期,但低于T4期。T0期患者的全因死亡率高于所有其他分期(T1-T4)。多变量Cox回归模型显示,在调整其他风险因素后,与T1期和T4期相比,T0期有显著的癌症特异性死亡风险,但与T2期或T3期相比则无;对于全因死亡率,与T4期相比,T0期有显著的全因死亡风险,但与T1-T3期患者相比则无。使用倾向得分匹配分析对影响因素进行匹配后,得到了类似的结果。发现T0期DTC患者出人意料的预后并不优于其他分期的DTC患者,这为T0期DTC患者的治疗提供了新的启示。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/759a/5642593/28d7a9431c1e/oncotarget-08-70777-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/759a/5642593/c6560b5b3e00/oncotarget-08-70777-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/759a/5642593/5f06115362fd/oncotarget-08-70777-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/759a/5642593/dca45799faf3/oncotarget-08-70777-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/759a/5642593/7f39d6caf5fd/oncotarget-08-70777-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/759a/5642593/a6ff5bff96a5/oncotarget-08-70777-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/759a/5642593/3bd83d748e8f/oncotarget-08-70777-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/759a/5642593/28d7a9431c1e/oncotarget-08-70777-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/759a/5642593/c6560b5b3e00/oncotarget-08-70777-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/759a/5642593/5f06115362fd/oncotarget-08-70777-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/759a/5642593/dca45799faf3/oncotarget-08-70777-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/759a/5642593/7f39d6caf5fd/oncotarget-08-70777-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/759a/5642593/a6ff5bff96a5/oncotarget-08-70777-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/759a/5642593/3bd83d748e8f/oncotarget-08-70777-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/759a/5642593/28d7a9431c1e/oncotarget-08-70777-g007.jpg

相似文献

1
Unanticipated prognosis of differential thyroid cancer patients with T0 stage: analysis of the SEER database 2004-2013.T0期分化型甲状腺癌患者的意外预后:2004 - 2013年监测、流行病学和最终结果(SEER)数据库分析
Oncotarget. 2017 Aug 7;8(41):70777-70787. doi: 10.18632/oncotarget.19988. eCollection 2017 Sep 19.
2
Prognosis of patients with TX stage differentiated thyroid cancer: propensity scored matching analysis of the SEER database 2004-2013.TX期分化型甲状腺癌患者的预后:2004 - 2013年SEER数据库的倾向评分匹配分析
Am J Transl Res. 2018 Jul 15;10(7):2004-2014. eCollection 2018.
3
Do patients with oxyphilic cell papillary thyroid carcinoma have a poor prognosis? Analysis of the surveillance, epidemiology, and end results database 2004-2013 with propensity score matching.嗜酸性细胞型甲状腺乳头状癌患者的预后是否较差?利用倾向评分匹配法对2004 - 2013年监测、流行病学及最终结果数据库进行分析。
Oncotarget. 2017 Aug 18;8(44):77075-77085. doi: 10.18632/oncotarget.20355. eCollection 2017 Sep 29.
4
The prognosis of NX stage differentiated thyroid cancer based on propensity score matching and SEER data.基于倾向评分匹配和监测、流行病学与最终结果(SEER)数据的NX期分化型甲状腺癌的预后
Am J Transl Res. 2018 Nov 15;10(11):3782-3789. eCollection 2018.
5
Patients Aged ≥55 Years With Stage T1-2N1M1 Differentiated Thyroid Cancer Should Be Downstaged in the Eighth Edition AJCC/TNM Cancer Staging System.年龄≥55岁的T1-2N1M1期分化型甲状腺癌患者在第八版美国癌症联合委员会/国际抗癌联盟(AJCC/TNM)癌症分期系统中应进行降期。
Front Oncol. 2019 Oct 18;9:1093. doi: 10.3389/fonc.2019.01093. eCollection 2019.
6
Propensity score matching analysis of the prognosis for the rare insular subtype of thyroid cancer based on SEER database.基于监测、流行病学和最终结果(SEER)数据库对罕见甲状腺癌岛叶亚型预后的倾向评分匹配分析。
Oncotarget. 2017 Oct 11;8(60):101623-101633. doi: 10.18632/oncotarget.21826. eCollection 2017 Nov 24.
7
DOES T STAGE AFFECT PROGNOSIS IN PATIENTS WITH STAGE IV B DIFFERENTIATED THYROID CANCER?IVA 期分化型甲状腺癌患者的 T 分期是否影响预后?
Endocr Pract. 2019 Sep;25(9):877-886. doi: 10.4158/EP-2019-0051. Epub 2019 Jun 6.
8
Paradoxes in thyroid carcinoma treatment: analysis of the SEER database 2010-2013.甲状腺癌治疗中的悖论:2010 - 2013年监测、流行病学和最终结果(SEER)数据库分析
Oncotarget. 2017 Jan 3;8(1):345-353. doi: 10.18632/oncotarget.13395.
9
Synergic effects of histology subtype, lymph node metastasis, and distant metastasis on prognosis in differentiated thyroid carcinoma using the SEER database.利用监测、流行病学和最终结果(SEER)数据库研究组织学亚型、淋巴结转移和远处转移对分化型甲状腺癌预后的协同作用。
Gland Surg. 2020 Aug;9(4):907-918. doi: 10.21037/gs-20-273.
10
Mixed subtype thyroid cancer: A surveillance, epidemiology, and end results database analysis.混合亚型甲状腺癌:一项监测、流行病学和最终结果数据库分析。
Oncotarget. 2017 Sep 23;8(49):86556-86565. doi: 10.18632/oncotarget.21242. eCollection 2017 Oct 17.

引用本文的文献

1
Prognosis of FTC compared to PTC and FVPTC: findings based on SEER database using propensity score matching analysis.与乳头状甲状腺癌(PTC)和滤泡状乳头状甲状腺癌(FVPTC)相比,滤泡状甲状腺癌(FTC)的预后:基于监测、流行病学和最终结果(SEER)数据库使用倾向评分匹配分析的结果
Am J Cancer Res. 2018 Aug 1;8(8):1440-1448. eCollection 2018.

本文引用的文献

1
Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.1974 - 2013年美国甲状腺癌发病率和死亡率趋势
JAMA. 2017 Apr 4;317(13):1338-1348. doi: 10.1001/jama.2017.2719.
2
Diagnostic accuracy of ultrasonographic features for lymph node metastasis in papillary thyroid microcarcinoma: a single-center retrospective study.超声特征对甲状腺微小乳头状癌淋巴结转移的诊断准确性:一项单中心回顾性研究
World J Surg Oncol. 2017 Jan 26;15(1):32. doi: 10.1186/s12957-017-1099-2.
3
A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis.
甲状腺乳头状癌经典型与高细胞变异型的临床病理特征及预后比较:一项荟萃分析
Oncotarget. 2017 Jan 24;8(4):6222-6232. doi: 10.18632/oncotarget.14055.
4
Exploring the Relationship Between Patient Age and Cancer-Specific Survival in Papillary Thyroid Cancer: Rethinking Current Staging Systems.探讨乳头状甲状腺癌患者年龄与癌症特异性生存率之间的关系:重新思考当前的分期系统。
J Clin Oncol. 2016 Dec 20;34(36):4415-4420. doi: 10.1200/JCO.2016.68.9372. Epub 2016 Oct 28.
5
Paradoxes in thyroid carcinoma treatment: analysis of the SEER database 2010-2013.甲状腺癌治疗中的悖论:2010 - 2013年监测、流行病学和最终结果(SEER)数据库分析
Oncotarget. 2017 Jan 3;8(1):345-353. doi: 10.18632/oncotarget.13395.
6
Biologic and Clinical Perspectives on Thyroid Cancer.甲状腺癌的生物学与临床视角
N Engl J Med. 2016 Sep 15;375(11):1054-67. doi: 10.1056/NEJMra1501993.
7
Recent incidences and differential trends of thyroid cancer in the USA.美国甲状腺癌的近期发病率及差异趋势。
Endocr Relat Cancer. 2016 Apr;23(4):313-22. doi: 10.1530/ERC-15-0445. Epub 2016 Feb 25.
8
Cancer statistics in China, 2015.《中国癌症统计数据 2015》
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.
9
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.2015年美国甲状腺协会成人甲状腺结节和分化型甲状腺癌管理指南:美国甲状腺协会甲状腺结节和分化型甲状腺癌指南工作组
Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020.
10
Long-Term Follow-Up of the Therapeutic Outcomes for Papillary Thyroid Carcinoma With Distant Metastasis.甲状腺乳头状癌伴远处转移治疗结果的长期随访
Medicine (Baltimore). 2015 Jul;94(26):e1063. doi: 10.1097/MD.0000000000001063.